Constant of Lung Cancer 中国肺癌杂志 CN 12-1395/R

首页 | 关于我们 | 登录 | 注册 | 搜索 | 最新一期 | 过刊浏览 | 公告 | 稿约 | 在线投稿 | Online submission ARTICLE TOOLS Endnote参考文献模板 提前在线出版 i 索引源数据 🖬 首页 > 卷 11, 编号 3 (2008) > LIN 💿 如何引证项目 🧧 查找参考文献 审查政策 Analysis of the relationship between the response after the First-line Email this article chemotherapy and the survival in the advanced non-small cell lung (Login required) cancer RELATED ITEMS Liping LIN, Xiaojuan XIANG, He HUANG, Hongyun ZHAO, Yang ZHANG, Jingxun WU, Yuanyuan ZHAO, Xuan WU, Li ZHANG Related studies 摘要 Databases Web search Background and objective Most patients with advanced non-small cell lung cancer (NSCLC) 📑 Show all treated with first-line chemotherapy consisted of the third generation new drug got the disease in control (CR+PR+SD). In this study, we retrospectively reviewed our data to investigate the difference of survival between patients of disease control and progression ABOUT THE (PD), and disease response (CR+PR) and stable (SD), to identify the prognosis factor AUTHORS correlated with survival. Methods In our retrospective study, 118 patients with stage IIIB (with malignancy pleural fluid) and IV NSCLC were identified who received the third Liping LIN generation new drug-based platinum or non-platinum regimens, the response of first-line chemotherapy were complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to RECIST criteria based on the records on the imaging reports papers. Results After first-line chemotherapy, 86 (72.9%) patients [CR2 (1.7%), PR47 Xiaojuan XIANG (39.8%), SD37 (31.4%)) had disease control and 33 (27.1%) patients had progression disease. The median survival time of CR+PR+SD arm was significantly longer than PD arm (17.8 months vs 8.4 months, P=0.001), but there was no significant difference between He HUANG CR+PR arm and SD arm (18.1 months vs 15.5 months, P=0.917), the PFS between two arms were no significantly different too (7.1 months vs 6.9 months, P=0.622). The Cox regression analysis shows that stage (IIIB or IV), chemotherapy lines (less than three lines or more Hongyun ZHAO than four lines) and disease control or not after first-line chemotherapy were independently prognosis factor of overall survival. Conclusion Our data shows that the survival of response and stable disease patients are better than that of patient with progression disease, the survival benefit of patients with stable disease and responses are no significantly difference. Yang ZHANG 关键词 Jingxun WU Lung neoplasms; Outcome; Chemotherapy; Prognosis factor 全文: PDF Yuanyuan ZHAO 🌏 Get Permission



🖸 ADD THIS 🛛 🚽 😭 🦓

Xuan WU

